Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.

导出 LinkOut

翻译打印收藏纠错

第一作者： Predrag,Nikic

第一单位： Clinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.;University of Belgrade, Faculty of Medicine, Belgrade, Serbia.

作者： Predrag,Nikic ^[1] ; Nada,Babovic ^[2] ; Zoran,Dzamic ^[1] ; Svetlana,Salma ^[3] ; Vesna,Stojanovic ^[4] ; Suzana,Matkovic ^[2] ; Zoran,Pejcic ^[3] ; Kristina,Juskic ^[2] ; Ivan,Soldatovic ^[5]

作者单位： Clinic of Urology, University Clinical Center of Serbia, Belgrade, Serbia.;University of Belgrade, Faculty of Medicine, Belgrade, Serbia. ^[1] Institute for Oncology and Radiology of Serbia, Belgrade, Serbia. ^[2] Oncology Institute of Vojvodina, Sremska Kamenica, Serbia. ^[3] University Clinical Center Nis, Clinic of Oncology, Nis, Serbia. ^[4] University of Belgrade, Faculty of Medicine, Belgrade, Serbia.;Institute of Medical Statistics and Informatics, Belgrade, Serbia. ^[5]

关键词 limited access to cancer therapy metastatic clear cell renal carcinoma (mRCC)overall survival (OS)pazopanib real world data sunitinib

DOI 10.3389/fonc.2022.892156

PMID 35756652

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交